Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please take note that Board of Directors ('Board') of the Company at its meeting held on May 28, 2019, considered and approved the Scheme of Amalgamation ('Scheme') pursuant to sections 230-232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of its wholly owned subsidiaries viz.,APL Healthcare Limited, APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited ('Transferor Companies') with Aurobindo Pharma Limited ('Transferee Company'). The Scheme would be subject to the requisite statutory/ regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench). Owing to changes in the business dynamics, the Restructuring Committee of Board of Directors of the Company at its meeting held today, September 7, 2020 has considered and approved modifications to the aforesaid Scheme pursuant to sections 230-232 and other applicable provisions of the Companies Act, 2013, whereby APL Healthcare Limited, a wholly owned subsidiary of the Company & Transferor Company 6, would be excluded from the Scheme and will accordingly, modify the Scheme and continue with the modified Scheme of Amalgamation of its wholly owned subsidiaries viz., APL Research Centre Limited and Aurozymes Limited and Curepro Parenteral Limited and Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited with Aurobindo Pharma Limited (Transferee Company). The modified Scheme would be subject to the requisite statutory / regulatory approvals including the approval of the Hon'ble National Company Law Tribunal, Bench at Hyderabad. (AS Per BSE Announcement Dated on 07.09.2020) We refer to our letters dated May 28, 2019 and June 3, 2019 informing about the Scheme of Amalgamation of wholly owned subsidiaries of Aurobindo Pharma Limited viz., APL Healthcare Limited and APL Research Centre Limited and Aurozymes Limited and Curepro Parenterals Limited and Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited with Aurobindo Pharma Limited and letters dated September 7, 2020 and September 14, 2020 informing about modified Scheme of Amalgamation whereby APL Healthcare Limited, a wholly owned subsidiary of the Company, would be excluded from the aforesaid Scheme. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the Hon''ble National Company Law Tribunal (NCLT), Hyderabad bench vide its order dated March 30, 2021, has approved the said modified Scheme of Amalgamation. A certified copy of the NCLT Order along with the Scheme is attached herewith for your reference. (AS Per BSE Announcement Dated on 08.04.2021) We refer to our letters dated May 28, 2019 & June 3, 2019 informing about the Scheme of Amalgamation of wholly owned subsidiaries of Aurobindo Pharma Ltd., viz., APL Healthcare Ltd., and APL Research Centre Ltd., and Aurozymes Ltd and Curepro Parenterals Limited and Hyacinths Pharma Private Ltd and Silicon Life Sciences Private Ltd with Aurobindo Pharma Ltd and letters dated September 7, 2020 and September 14, 2020 informing about modified Scheme of Amalgamation whereby APL Healthcare Ltd, a wholly owned subsidiary of the Company, would be excluded from the aforesaid Scheme. We have intimated to you on April 8, 2021, pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, that the Hon''ble National Company Law Tribunal (NCLT), Hyderabad bench vide its order dated March 30, 2021, had approved the said modified Scheme of Amalgamation. We would like to inform you that we have filed the certified copy of the said order today with the Registrar of Companies, Hyderabad. (As Per BSE Announcement dated on 29.04.2021)